Document is current
Any future updates will be listed below
-
Authors
Flinkenflügel, Kira https://orcid.org/0000-0001-7738-5429
Borgers, Tiana
Klug, Melissa https://orcid.org/0000-0002-2234-4096
Mummendey, Marie M.
Leehr, Elisabeth J.
Meinert, Susanne https://orcid.org/0000-0003-2177-7161
Gruber, Marius
Repple, Jonathan https://orcid.org/0000-0003-1379-9491
Kircher, Tilo https://orcid.org/0000-0002-2514-2625
Opel, Nils https://orcid.org/0000-0003-4749-3298
Bauer, Jochen https://orcid.org/0000-0001-9345-2126
Zwiky, Esther https://orcid.org/0000-0002-6733-8087
König, Philine
Küttner, Antonia
Schöniger, Konrad https://orcid.org/0000-0002-1849-9490
Kamrla, Robin
Dannlowski, Udo https://orcid.org/0000-0002-0623-3759
Enneking, Verena
Redlich, Ronny
- License Information
-
More Information
Article History
Received: 15 October 2024
Revised: 16 January 2025
Accepted: 10 February 2025
First Online: 26 February 2025
Competing interests
: JR received speaking honoraria from Janssen, Hexal and Novartis. Tilo Kircher received unrestricted educational grants from Servier, Janssen, Recordati, Aristo, Otsuka, neuraxpharm. All other authors state that they have no actual or potential conflict of interest to declare, including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could influence or bias their work.
